KIROMIC BIOPHARMA
Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Their cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
KIROMIC BIOPHARMA
Industry:
Bioinformatics Biopharma Biotechnology Health Care Life Science Pharmaceutical Therapeutics
Founded:
2012-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.kiromic.com
Total Employee:
11+
Status:
Active
Contact:
806-252-5845
Email Addresses:
[email protected]
Total Funding:
53.24 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
ImmunoBiochem Corporation
ImmunoBiochem is developing novel tumor microenvironment-targeted biological therapeutics for solid tumor indications.
Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-06-14 | In Silico Solutions | In Silico Solutions acquired by Kiromic Biopharma | N/A |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-12 | Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer |
| 2021-10-05 | Kiromic BioPharma Announces Chief Financial Officer Transition |
Official Site Inspections
http://www.kiromic.com Semrush global rank: 6.92 M Semrush visits lastest month: 694
- Host name: host2001.hostmonster.com
- IP address: 67.20.76.53
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Kiromic Biopharma"
Kiromic Biopharma - Crunchbase Company Profile
Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented …See details»
Kiromic Biopharma Company Profile - Office Locations ... - Craft
Oct 29, 2024 Kiromic BioPharma (formerly known as Kiromic) is a target discovery and gene editing company focusing on developing immuno-oncology therapeutics for the treatment of …See details»
Kiromic Biopharma - Org Chart, Teams, Culture & Jobs - The Org
Kiromic Biopharma is an immuno-oncology, target discovery, and gene editing company developing highly effective and safe tumor-specific cancer engineered immunotherapies to …See details»
About - Management - Kiromic
Deprecated: Creation of dynamic property WPRMenu_Styles::$wprmenu_options is deprecated in /home2/kiromicc/public_html/wp-content/plugins/wp-responsive-menu/inc ...See details»
Leadership - Kiromic
Dr. Dahlbeck has served as our Chief of Staff since February 2022. He previously served as our President from January 2013 to October 2019, and Chief Medical Officer from October 2019 to …See details»
KIROMIC, LLC - VentureRadar
" Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell and …See details»
Kiromic BioPharma, Inc.: Governance, Directors and Executives ...
Mar 14, 2023 Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company. The Company is engaged in developing a multi-indication allogeneic cell therapy …See details»
Kiromic - Overview, News & Similar companies | ZoomInfo.com
May 27, 2024 Who is Kiromic. Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND AI (artificial intelligence) pl atform to …See details»
Kiromic BioPharma, Inc.
Kiromic BioPharma, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4762913 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer …See details»
Kiromic Company Profile | Management and Employees List
Kiromic is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of g amma delta T-cells to target solid cancers. …See details»
Kiromic - Company Profile - Tracxn
Dec 18, 2024 Kiromic - Developer of small molecules-based therapeutic solutions for the treatment of cancer. Public Company. Raised a total funding of $135K over 1 round. Founded …See details»
Kiromic BioPharma Announces Changes in Management
Feb 3, 2022 Kiromic's DIAMOND is where big data science meets target identification to dramatically compress the man-years and billions of drug development dollars required to …See details»
About KIROMIC BIOPHARMA, INC. | DxMultiomics
KIROMIC BIOPHARMA, INC. | on DxMultiomics. Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) …See details»
Kiromic Biopharma - Funding, Financials, Valuation & Investors
Kiromic Biopharma is registered under the ticker NASDAQ:KRBP . Their stock opened with $12.00 in its Oct 15, 2020 IPO. Kiromic Biopharma has a post-money valuation in the range of …See details»
Kiromic furloughs 'substantially all' workers amid cash crunch
Mar 18, 2025 Kiromic switched its focus to Deltacel in 2022, one year after raising $40 million to fund development of two other candidates. The Securities and Exchange Commission recently …See details»
Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to ...
Jan 28, 2022 Kiromic is in the process of developing a multi-indication allogeneic CAR-T cell therapy that exploits the natural potency of Gamma Delta T-cells to target solid cancers. From …See details»
Kiromic BioPharma Files for Chapter 7 Bankruptcy
Mar 21, 2025 Kiromic BioPharma said it has filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the district of Delaware. In a filing to the Securities and Exchange …See details»
Kiromic Biopharma - Contacts, Employees, Board Members
Kiromic develops biomarker- and small molecule-based diagnostic and therapeutic programs for solid tumors and hematologic malignancies. ... Experience the new Crunchbase, powered by …See details»
Houston cancer treatment company declares bankruptcy shortly …
Mar 21, 2025 In the same submission to the Securities and Exchange Commission, the organization announced it had relieved CFO Brian Hungerford of his duties, as well as …See details»
Kiromic Biopharma - workinbiotech.com
Kiromic Biopharma is addressing solid tumors through the development of allogeneic gamma delta T-cell therapies. To develop these therapies Kiromic is using Diamond AI, a neural …See details»